Cairn Surgical, a Lebanon, NH-based medical technology firm, raised $4.5M in funding.
The round was led by Morningside Ventures.
The company intends to use the funds to complete the currently-enrolling U.S. pivotal trial of its Breast Cancer Locator (BCL™) system and implement a limited commercial launch of the technology in select European markets.
Led by CEO David Danielsen, CairnSurgical is developing patient-specific guides using patient imaging data and 3D printing technologies that are commercially available in Europe and being studied in a U.S. pivotal trial. Its breast cancer locator (BCL) system is designed to enable precise tumor localization and excision. The BCL System is personalized to each patient and based on a supine MRI of their breast in its surgical position for greatest accuracy. The BCL System is a customized 3D-printed form that fits the unique shape of that patient’s breast and is intended to guide the surgeon to the tumor’s boundaries and margins. An interactive 3D computer model of the tumor in the breast showing tumor shape, size and location is also provided to the surgeon.
FinSMEs
21/08/2024